The Valley Desk

NCT00503243 · Interventional trial

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Overall registry status Completed

Phase 3

Conditions Colitis, Ulcerative

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov